Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Inclusion Criteria: * Pathologically confirmed diagnosis of refractory cancer that has failed at least prior line of conventional standard of care therapy. * Diagnosed with any histologically confirmed malignancy whose disease is confirmed to be metastatic and/or unresectable for which standard curative or beneficial treatments are no longer effective. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * ≥ 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational). * ≥ 2 weeks since prior palliative radiotherapy. * Complete recovery to baseline or Grade 1 NCI CTCAE v5.0 from AE of prior surgery, radiotherapy, endocrine therapy, and other therapy as applicable, with exception of grade 2 alopecia from prior chemotherapy. * Adequate bone marrow function: * Neutrophils: ≥ 1.5 K/µL without colony-stimulating factor support * Platelet Count: ≥ 100 K/µL * Hemoglobin: ≥ 9.0 g/dL without need for hematopoietic growth factor or transfusion support * No ongoing transfusion requirements * Adequate hepatic function: * Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), does not apply to patients with Gilbert's syndrome * Serum albumin ≥ 3.0 g/dL * ALT and AST ≤ 2.5 × ULN, unless hepatic metastases are present then \< 5 x ULN * Adequate renal function with creatinine ≤ 2.0 mg/dL. * Coagulation: INR or aPTT ≤1.5 X ULN unless the subject is receiving anticoagulant …